DNER and neoplasm: Here, we show that combining BET inhibition with irinotecan to indirectly target oncogenic signaling is able to induce tumor regression, with two of the three PDAC PDX models tested reaching partial response, including one model of the difficult-to-treat basal (or quasi mesenchymal) subtype.